The objective of this study was to find a new parameter to monitor bleeding tendency after
dabigatran etexilate (Pradaxa) medication in Chinese nonvalvular atrial fibrillation patients …

Introduction Although dabigatran, an oral direct thrombin inhibitor, does not require routine
monitoring, high plasma concentration of dabigatran (PDC) at trough level is shown to be a …

Background: Few data exist regarding frequency and predictors of bleeding complications
associated with anticoagulant therapy using dabigatran in Japanese patients with atrial …

Special circumstances may require the measurement of the anticoagulant effect of
dabigatran etexilate. No data currently link any given coagulation test to bleeding outcomes …

Background Activated partial thromboplastin time (aPTT) is recommended for monitoring
anticoagulant activity in dabigatran-treated patients; however, there are limited data in …

This study aimed to evaluate the variability of dabigatran plasma concentration and the
association with clinical events in Chinese patients treated with dabigatran etexilate (DE) for …

Aims In patients with atrial fibrillation prescribed dabigatran, the aim was to examine the
correlation between plasma dabigatran concentrations and the three screening coagulation …

Purpose The purpose of this study was to analyze the association between bleeding events
and coagulation assays including activated partial thromboplastin time (APTT) and …

Introduction Warfarin and dabigatran are used to prevent thromboembolism in patients with
atrial fibrillation (AF). Although these medications can effectively prevent ischemic stroke …

Background Novel oral anticoagulants and warfarin are widely used for stroke prevention in
patients with atrial fibrillation. The anticoagulation status of patients receiving warfarin or …